Patents Assigned to Genentech
  • GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20220098668
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Applicant: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • METHODS FOR DETECTING AND QUANTIFYING MEMBRANE-ASSOCIATED PROTEINS
    Publication number: 20220099677
    Abstract: The present disclosure provides assays for the detection and/or quantification of membrane-associated proteins, e.g., circulating CD20 (cCD20), incorporating an extracellular vesicle-based calibrator comprising the membrane-associated tumor antigen as well as the use of such assays in the detection and treatment of hyperproliferative disorders.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 31, 2022
    Applicant: GENENTECH, INC.
    Inventors: Vinita GUPTA, Ann Therese BRADY, James Thomas KOERBER, Xiangdan WANG, Minh Michael Nhu PHAN, Yonglian SUN
  • METHODS OF TREATING ALZHEIMER'S DISEASE
    Publication number: 20220098288
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Application
    Filed: May 26, 2021
    Publication date: March 31, 2022
    Applicant: Genentech, Inc.
    Inventor: Robert GRAHAM
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 11286302
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • KLOTHO BETA
    Publication number: 20220089780
    Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.
    Type: Application
    Filed: August 25, 2021
    Publication date: March 24, 2022
    Applicant: Genentech, Inc.
    Inventor: Luc Desnoyers
  • Compositions and methods for regulating cell osmolarity
    Patent number: 11279939
    Abstract: The invention provides compositions and methods for regulating intracellular osmolarity in cells, e.g., in cultured cells, including in cultured cells in bioreactors. The invention provides nucleic acids comprising at least one osmo-responsive transcriptional regulatory element (OR-TRE), and cells, vectors, products of manufacture, artificial organs or implants and the like containing an osmo-responsive transcriptional regulatory element (OR-TRE).
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 22, 2022
    Assignee: GENENTECH, INC.
    Inventors: Laetitia Malphettes, Andrew Snowden, Inn H. Yuk
  • Therapeutic and diagnostic methods for cancer
    Patent number: 11279767
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: March 22, 2022
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: Richard Bourgon, David Fabrizio, Gregg Fine, Garrett M. Frampton, Priti Hegde, Sanjeev Mariathasan, Philip J. Stephens, James Xin Sun, Roman Yelensky
  • Cyclic peptide antibiotics
    Patent number: 11279735
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 22, 2022
    Assignee: Genentech, Inc.
    Inventors: Emily J. Hanan, Georgette Castanedo, Marie Gabrielle Braun, Keira Garland, Peter Andrew Smith, Richard Pastor, Paul Gibbons, Yunxing Cheng, Guosheng Wu, Yuhong Fu, Po-Wai Yuen
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11279687
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng, Po-Wai Yuen
  • Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
    Patent number: 11279762
    Abstract: The invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: March 22, 2022
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Angie Yee, Christine Tan, Joyce Lai, Joanne Adamkewicz, John Byon
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20220081423
    Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain.
    Type: Application
    Filed: May 26, 2021
    Publication date: March 17, 2022
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI, Zhiguo LIU, Wenfeng LIU, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
  • ENHANCED PROTEIN PURIFICATION THROUGH A MODIFIED PROTEIN A ELUTION
    Publication number: 20220081466
    Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.
    Type: Application
    Filed: May 27, 2021
    Publication date: March 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Arick BROWN, Christopher J. DOWD, Asha Nandini-Radhamohan KEBA
  • SYNTHESIS OF QUINAZOLINE COMPOUNDS
    Publication number: 20220081413
    Abstract: Provided herein are methods of synthesizing quinazoline compounds comprising at least one atropisomeric center.
    Type: Application
    Filed: August 10, 2021
    Publication date: March 17, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Ngiap-Kie Lim, Jeff Shen, Lauren E. Sirois, Jacob C. Timmerman, Etienne Trachsel, Nicholas A. White, Jie Xu, Haiming Zhang, Stephan Bachmann, Raphael Bigler, Kyle Bradley Pascual Clagg, Antonio Dipasquale, Francis Gosselin, Ugo Jonathan Orcel, Roland Christoph Meier
  • Anti-polyubiquitin multispecific antibodies
    Patent number: 11274145
    Abstract: The invention provides antibodies that bind mixed-topology polyubiquitin and multispecific anti-polyubiquitin antibodies, and methods of using the same.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 15, 2022
    Assignee: Genentech, Inc.
    Inventors: Vishva Dixit, Marissa Matsumoto, Erick Castellanos
  • CINNOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20220073520
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: March 26, 2021
    Publication date: March 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE
    Publication number: 20220064315
    Abstract: Provided herein are tetravalent antigen binding complexes having agonist activity for a cell surface receptor. In some embodiments, the complexes comprise binding specificities for multiple epitopes of the same cell surface receptor. Further provided herein are nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production related thereto.
    Type: Application
    Filed: May 17, 2021
    Publication date: March 3, 2022
    Applicant: Genentech, Inc.
    Inventors: Greg LAZAR, Yanli YANG, Erin H. CHRISTENSEN, Julie HANG, Jeong KIM, Seth HARRIS
  • METHODS OF PURIFYING POLYPEPTIDES
    Publication number: 20220064209
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Application
    Filed: July 7, 2021
    Publication date: March 3, 2022
    Applicant: Genentech, Inc.
    Inventors: Hui F. LIU, Brian David KELLEY, Deanna E. MYERS, Beth MCCOOEY, Krista Marie PETTY
  • ANTIBODIES AND METHODS OF USE
    Publication number: 20220064331
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: June 8, 2021
    Publication date: March 3, 2022
    Applicant: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Methods for diagnosing and treating inflammatory bowel disease
    Patent number: 11261493
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: March 1, 2022
    Assignee: GENENTECH, INC.
    Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
  • Defect detection in lyophilized drug products with convolutional neural networks
    Patent number: 11263738
    Abstract: In one embodiment, a method includes receiving one or more querying images associated with a container of a pharmaceutical product, each of the one or more querying images being based on a particular angle of the container of the pharmaceutical product, calculating one or more confidence scores associated with one or more defect indications, respectively for the container of the pharmaceutical product, by processing the one or more querying images using a target machine-learning model, and determining a defect indication for the container of the pharmaceutical product from the one or more defect indications based on a comparison between the one or more confidence scores and one or more predefined threshold scores, respectively.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 1, 2022
    Assignee: GENENTECH, INC.
    Inventors: Zheng Li, Calvin Tsay